Related Experiment Videos
Recombinant activated factor VII (rFVIIa, NovoSeven)
1Department of Haematology, Bombay Hospital Institute of Medical Sciences, Marine lines, Mumbai-400020, India.
The Journal of the Association of Physicians of India
|January 10, 2006
Summary
Recombinant activated factor VII (rFVIIa) effectively stops bleeding by acting locally at injury sites. This safe and well-tolerated hemostatic agent is approved for hemophilia and other bleeding disorders.
Area of Science:
- Hematology
- Pharmacology
Background:
- Recombinant activated factor VII (rFVIIa) is a procoagulant agent.
- Its primary approved indications include bleeding in hemophilia patients with inhibitors and Factor VII deficiency.
Purpose of the Study:
- To review the expanding applications of rFVIIa as a general hemostatic agent beyond its licensed uses.
- To summarize evidence supporting its efficacy and safety in various bleeding conditions.
Main Methods:
- Review of published literature including case series, anecdotal reports, and clinical trials.
- Analysis of data on rFVIIa's hemostatic effects and safety profile.
Main Results:
- rFVIIa demonstrates efficacy in diverse bleeding conditions such as liver disease, thrombocytopenia, trauma, and intracerebral hemorrhage.
- It is also effective in reversing anticoagulant toxicity.
- Clinical trials indicate rFVIIa is generally safe and well-tolerated, with rare thrombotic events.
Conclusions:
- rFVIIa is a valuable hemostatic agent with a broad range of applications.
- Its use is supported by growing evidence for efficacy and a favorable safety profile in various bleeding scenarios.